Bright Minds Biosciences (DRUG) 20-F 29 Dec 22 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Sep. 30, 2022 shares
Entity Addresses [Line Items]
Entity Registrant Name	BRIGHT MINDS BIOSCIENCES INC.
Entity Central Index Key	0001827401
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Entity File Number	001-40997
Document Period End Date	Sep. 30, 2022
Entity Address, Address Line One	19 Vestry Street
Entity Address, City or Town	NY
Entity Address, State or Province	NY
Entity Incorporation, State or Country Code	Z4
Entity Address, Country	US
Entity Address, Postal Zip Code	10013
Title of 12(b) Security	Common Shares
Trading Symbol	DRUG
Security Exchange Name	NASDAQ
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	17,592,359
Document Accounting Standard	International Financial Reporting Standards
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Interactive Data Current	Yes
Document Transition Report	false
Document Shell Company Report	false
Entity Ex Transition Period	false
Auditor Firm ID	1054
Auditor Name	De Visser Gray LLP
Auditor Location	Vancouver, Canada
Business Contact [Member]
Entity Addresses [Line Items]
Contact Personnel Name	Ian McDonald
Entity Address, Address Line One	19 Vestry Street
Entity Address, City or Town	NY
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10013
City Area Code	647
Local Phone Number	407-2515
Contact Personnel Email Address	ian@brightmindsbio.com

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($)	Sep. 30, 2022	Sep. 30, 2021
Current assets
Cash and cash equivalents	$ 11,627,913	$ 19,760,015
Sales tax receivable	114,518	110,146
Other receivables	41,261	0
Prepaids	164,429	168,207
Total current assets	11,948,121	20,038,368
Non-current assets
Right-of-use asset	138,863	0
Intangible assets	0	2,000
Total assets	12,086,984	20,040,368
Current liabilities
Accounts payable and accrued liabilities	1,404,561	638,573
Lease liability - current portion	67,928	0
Total current liabilities	1,472,489	638,573
Non-Current Liabilities
Lease liability - non-current portion	71,983	0
TOTAL LIABILITIES	1,544,472	638,573
Shareholders' equity
Share capital	32,237,844	27,080,281
Subscription receivable	0	(33,684)
Reserves	2,479,466	1,565,055
Deficit	(24,174,798)	(9,209,857)
TOTAL SHAREHOLDERS' EQUITY	10,542,512	19,401,795
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 12,086,984	$ 20,040,368

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
EXPENSES
Consulting fees	$ 771,329	$ 394,624	$ 0
Directors' compensation	99,438	136,612	0
Foreign exchange	(12,151)	(154,099)	0
Funds processing fees - private placements	0	18,665	5,568
Marketing, advertising, and investor relations	551,864	852,151	9,618
Office and administrative	478,248	197,125	637
Professional fees	650,196	709,954	104,251
Regulatory and filing	243,079	181,743	5,451
Research and development	12,180,938	6,313,988	354,852
TOTAL EXPENSES	(14,962,941)	(8,650,763)	(480,377)
Impairment of intangible assets	(2,000)	0	0
Net loss and comprehensive loss	$ (14,964,941)	$ (8,650,763)	$ (480,377)
Basic and diluted loss per share	$ (1.21)	$ (0.96)	$ (0.13)
Weighted average number of common shares outstanding -basic and diluted	12,351,917	8,974,023	3,612,436

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($)	Share capital [Member]	Subscriptions receivable [Member]	Subscriptions received [Member]	Reserves [Member]	Deficit [Member]	Total
Balance at Sep. 30, 2019	$ 205,980	$ (81,980)	$ 0	$ 0	$ (78,717)	$ 45,283
Balance (shares) at Sep. 30, 2019	4,119,600
Private placement	$ 779,924	80,980	147,426	0	0	1,008,330
Private placement (shares)	623,941
Share issue costs	$ (5,243)	0	0	0	0	(5,243)
Share-based compensation	0	0	0	161,300	0	161,300
Net and comprehensive loss	0	0	0	0	(480,377)	(480,377)
Balance at Sep. 30, 2020	$ 980,661	(1,000)	147,426	161,300	(559,094)	729,293
Balance (shares) at Sep. 30, 2020	4,743,541
Private placement	$ 27,924,936	(32,684)	(147,426)	0	0	27,744,826
Private placement (shares)	5,049,021
Finder's fees - cash	$ (1,516,317)	0	0	0	0	(1,516,317)
Finder's fees - broker warrants	(521,000)	0	0	521,000	0	0
Finder's fees - share options	(2,140)	0	0	2,140	0	0
Debt settlement with shares	$ 18,500	0	0	0	0	18,500
Debt settlement with shares (shares)	14,799
Share issue costs	$ (290,309)	0	0	0	0	(290,309)
Special warrant conversion	$ 20,000	0	0	0	0	20,000
Special warrant conversion (shares)	16,000
Warrants exercised	$ 97,400	0	0	0	0	97,400
Warrants exercised (shares)	1,948,000
Shares issued to the University	$ 368,550	0	0	0	0	368,550
Shares issued to the University (shares)	63,000
Share-based compensation	$ 0	0		880,615	0	880,615
Net and comprehensive loss	0	0	0	0	(8,650,763)	(8,650,763)
Balance at Sep. 30, 2021	$ 27,080,281	(33,684)	0	1,565,055	(9,209,857)	19,401,795
Balance (shares) at Sep. 30, 2021	11,834,361
Private placement	$ 4,001,200	33,684	0		0	4,034,884
Private placement (shares)	2,858,000
Finder's fees - cash	$ (539,329)	0	0	0	0	(539,329)
Finder's fees - compensation warrants	(531,000)	0	0	531,000	0	0
Finder's fees - share options	(39,355)	0	0	39,355	0	0
Share issue costs	(260,650)	0	0	0	0	(260,650)
Warrants exercised	$ 1,653,170	0	0	0	0	1,653,170
Warrants exercised (shares)	2,649,800
Compensation warrants exercised	$ 846,277	0	0	(531,000)	0	315,277
Compensation warrants exercised (shares)	225,198
Shares issued to a consultant	$ 27,250	0	0	0	0	27,250
Shares issued to a consultant (shares)	25,000
Share-based compensation	$ 0	0	0	875,056	0	875,056
Net and comprehensive loss	0	0	0	0	(14,964,941)	(14,964,941)
Balance at Sep. 30, 2022	$ 32,237,844	$ 0	$ 0	$ 2,479,466	$ (24,174,798)	$ 10,542,512
Balance (shares) at Sep. 30, 2022	17,592,359

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss for the year	$ (14,964,941)	$ (8,650,763)	$ (480,377)
Non-cash items:
Depreciation - Right-of-use asset	6,037	0	0
Foreign exchange	(258,824)	(223,787)	0
Shares recorded as consulting fees	27,250	0	0
Shares recorded as research and development	0	368,550	0
Share-based compensation	875,056	880,615	161,300
Interest on lease liability	2,173	0	0
Impairment of intangible assets	2,000	0	0
Changes in non-cash operating working capital items:
Sales tax receivable	(4,372)	(110,146)	0
Other receivables	(41,261)
Prepaids	3,778	(89,920)	(78,287)
Accounts payable and accrued liabilities	765,988	506,150	108,972
Net cash used in operating activities	(13,587,116)	(7,319,301)	(288,392)
Financing activities
Private placement proceeds	4,034,884	27,744,826	1,008,330
Finder's fees	(539,329)	(1,516,317)	0
Share issue costs	(260,650)	(290,309)	0
Special warrant proceeds	0	22,875	0
Refund of special warrant proceeds	0	(2,875)	0
Warrant exercise proceeds	1,653,170	97,400	0
Compensation warrant exercise proceeds	315,277	0	0
Principal portion of lease liability	(7,162)	0	0
Net cash from financing activities	5,196,190	26,055,600	1,008,330
Change in cash and cash equivalents	(8,390,926)	18,736,299	719,938
Effect of foreign exchange on cash	258,824	223,787	0
Cash and cash equivalents, beginning of year	19,760,015	799,929	79,991
Cash and cash equivalents, end of year	11,627,913	19,760,015	799,929
SUPPLEMENTARY INFORMATION
Debt settled by issuing shares	0	18,500	0
Fair value ascribed by brokers' warrants issued	0	521,000	0
Fair value of options issued as finders' fees	39,355	2,140	0
Share issue costs included in accounts payable	$ 0	$ 0	$ 5,243

NATURE AND CONTINUANCE OF OPERA

NATURE AND CONTINUANCE OF OPERATIONS	12 Months Ended
	Sep. 30, 2022
Nature And Continuance Of Operations [Abstract]
NATURE AND CONTINUANCE OF OPERATIONS [Text Block]	1. NATURE AND CONTINUANCE OF OPERATIONS Bright Minds Biosciences Inc. (the "Company") was incorporated under the Business Corporations Act of British Columbia on May 31, 2019. The Company's objective is to generate income and achieve long term profitable growth through the development of therapeutics to improve the lives of patients with certain severe and life-altering diseases. On February 8, 2021, the Company started trading on the Canadian Stock Exchange ("CSE") under the symbol DRUG. On May 17, 2021, the Company started trading on the OTCQB under the symbol BMBIF. On November 8, 2021, the Company started trading on the NASDAQ under the symbol DRUG. The registered address of the Company is located at 1500 - 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7, Canada. The head office address of the Company is located at 19 Vestry Street, New York, NY 10013, USA. These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2022, the Company is not able to finance day to day activities through operations and has incurred a loss of $14,964,941 for the year ended September 30, 2022. The Company has a deficit of $24,174,798 since inception and negative operating cash flows. As at September 30, 2022, the Company has working capital of $10,475,632 (September 30, 2021 - $19,399,795). The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds therefrom. Management intends to finance operating costs with equity financings, loans from directors and companies controlled by directors and/or private placement of common shares. The coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities specifically related to possible disruptions in the operations of the laboratories upon whom the Company relies, including laboratories situated in various parts of the United States and Europe. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.

STATEMENT OF COMPLIANCE AND BAS

STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION	12 Months Ended
	Sep. 30, 2022
Statement Of Compliance And Basis Of Preparation [Abstract]
STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION [Text Block]	2. STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION These consolidated financial statements were approved for issue on December 22, 2022 by the directors of the Company. Statement of compliance These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. Basis of preparation Depending on the applicable IFRS requirements, the measurement basis used in the preparation of these consolidated financial statements is cost, net realizable value, fair value or recoverable amount. These consolidated financial statements, except for the statement of cash flows, are based on the accrual basis.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2022
Disclosure Of Detailed Information About Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES [Text Block]	3. Basis of consolidation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021. On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated. Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these consolidated financial statements. Critical accounting estimates The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these consolidated financial statements. Ability to continue as a going concern Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments. Share-based compensation The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date. The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur. Foreign currency translation The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss. Business combinations The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss. Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses. Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred. Internally generated intangible assets - Research and development expenditure Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: • The technical feasibility of completing the intangible asset so that it will be available for use or sale; • The intention to complete the intangible asset and use or sell it; • The ability to use or sell the intangible asset; • How the intangible asset will generate probable future economic benefits; • The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and • The ability to measure reliably the expenditure attributable to the intangible asset during its development. The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred. Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately. At September 30, 2022 and 2021, the Company has not recognized any internally-generated intangible assets. Share-based compensation awards Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital. For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout. Provisions A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss. Income taxes Current income tax: Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income. Deferred tax: Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority. Loss per share Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share. Share capital Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments. Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax. Financial instruments Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets (a) Recognition and measurement of financial assets The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument. (b) Classification of financial assets The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL"). (i) Financial assets measured at amortized cost A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost: • The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows. • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding. A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary. (ii) Financial assets measured at FVTOCI A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss. (iii) Financial assets measured at FVTPL A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises. The Company's cash and cash equivalents are classified as subsequently measured at FVTPL. (c) Derecognition of financial assets The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the consolidated statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss. Financial liabilities (a) Recognition and measurement of financial liabilities The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument. (b) Classification of financial liabilities (i) Financial liabilities measured at amortized cost A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method. The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost. (ii) Financial liabilities measured at fair value through profit or loss A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises. (c) Derecognition of financial liabilities The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the consolidated statement of comprehensive loss. Offsetting financial assets and liabilities Financial assets and liabilities are offset and the net amount is presented in the consolidated statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Impairment of financial assets The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit losses. The Company recognizes in the consolidated statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Leases Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration. The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset. As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. Right-of-use asset The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received. The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset. In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability. Lease liability A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method. New standards and interpretations not yet adopted A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2022 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future: IAS 1 - Presentation of Financial Statements An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period. IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor." IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors IAS 8 amended the definition of material reflect the changes outlined above under IAS 1. IAS 12 and IFRIC 23 - Income Taxes IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Sep. 30, 2022
Share Exchange And Assignment [Abstract]
INTANGIBLE ASSETS [Text Block]	4. Psilocybinlabs Ltd. ("PL") was incorporated under the laws of the province of British Columbia on April 25, 2019, with the incorporator share being held by a company controlled by the CEO of the Company. On May 17, 2019, this share was transferred to the Company. On April 25, 2019, PL entered into a confirmatory assignment and waiver (the "CAW") with an individual, which was amended and restated on May 17, 2019. Pursuant to the amended and restated CAW, this individual assigned all of the right, title and interest, including all other intellectual property rights (the Rights, as described) to PL. As compensation for the assignment of the Rights, PL issued 100,000 common shares valued at $2,000 to this individual. On August 7, 2019, the Company then purchased the 100,000 common shares of PL by issuing 100,000 common shares of the Company valued at $2,000, with the reacquisition being recorded as an asset acquisition. On September 29, 2022, the directors of the Company agreed to wind-up and dissolve the subsidiary of the Company, PL and the carrying value of the intangible asset was impaired during the year ended September 30, 2022.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Sep. 30, 2022
Trade and other current payables [abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Text Block]	5. September 30, 2022 September 30, 2021 $ $ Accounts payable 1,246,384 596,573 Accrued liabilities 158,177 42,000 Total accounts payable and accrued liabilities 1,404,561 638,573

SHARE CAPITAL

SHARE CAPITAL	12 Months Ended
	Sep. 30, 2022
Disclosure of classes of share capital [abstract]
SHARE CAPITAL [Text Block]	6. SHARE CAPITAL Authorized share capital Unlimited number of common shares without par value. On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis. All common shares, stock options and warrant references in these consolidated financial statements reflect the effect of the share consolidation. Issued share capital for the year ended September 30, 2022 On April 11, 2022, the Company entered into a scientific advisory board agreement with Karl Deisseroth ("Deisseroth") pursuant to which the Company will pay Deisseroth a monthly fee of US$4,166.66 and issued an aggregate 25,000 common shares (the "Payment Shares") in the capital of the Company at a fair market value of $1.09 per share (total fair market value of $27,250). The Payment Shares will be issued in escrow and released to Deisseroth over a period of four years commencing on March 8, 2023 (see Note 8). On August 30, 2022, the Company issued 2,858,000 Units of the Company at a price per unit of $1.40 for aggregate gross proceeds of $4,001,200. Each Unit is comprised of one common share and one common share purchase warrant of the Company. Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $1.76 per share until August 30, 2024. The agent was paid a cash finder's fee $280,084 and expenses of $176,065 and received compensation warrants entitling them to purchase an aggregate of 134,040 Units of the Company at a per unit price of $1.40 for a period of twenty-four months following closing, with the Units having the same terms as the Units sold pursuant to the Offering. An advisor was additionally paid a cash finder's fee of $259,245 and received compensation warrants entitling them to purchase an aggregate of 91,158 Units of the Company at a per unit price of $1.40 for a period of twenty-four months following closing, with the Units having the same terms as the Units sold pursuant to the Offering. The Company incurred additional share issue costs of $84,585 in connection with the offering. In September 2022, 225,198 compensation warrants were exercised for gross proceeds of $315,277. Upon exercise, $531,000 was reclassified from reserves to share capital. During the year ended September 30, 2022, 2,649,800 warrants priced at $0.05, $1.76, and $9.46 per unit were exercised for gross proceeds of $1,653,170. Issued share capital for the year ended September 30, 2021 On November 2, 2020, the Company closed the second tranche of a non-brokered private placement financing through the issuance of 1,629,138 common shares at a price $1.25 per common share for gross proceeds of $2,036,422. On January 6, 2021, the Company issued 14,799 common shares at a deemed price of $1.25 per share to settle an $18,500 debt owing to a consultant pursuant to a debt settlement agreement entered into by the Company with the consultant. On February 3, 2021, the 16,000 SWs were deemed to be exercised for SW shares and 16,000 common shares of the Company were issued to the SW holders (see below). On March 17, 2021, the Company issued 3,419,883 Units at a price per Unit of $7.57 for aggregate gross proceeds of $25,888,514. Each Unit comprised one common share and one-half of one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company at an exercise price of $9.46 per share until March 17, 2024, subject to adjustment and acceleration in certain events. If the daily volume weighted average trading price of the common shares on the CSE is equal to or greater than $13.25 per common share for any 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration. The underwriters were paid fees for their services in the amount of $916,317 and received compensation warrants entitling them to purchase an aggregate of 132,666 common shares at a price of $7.57 per common share for a period of thirty-six months following closing. These warrants have an ascribed value of $521,000. On February 17, 2022, the Company received $33,684 in share subscriptions receivable related to this financing. On April 6, 2021, the Company paid a New York-based company (the "Finder") a contingent cash fee in the amount of $600,000, being 4.5% of $13,333,333 in net equity proceeds received from three investors introduced to the Company by the Finder. The Finder was also entitled to receive compensation warrants allowing it to purchase an aggregate of 8,807 common shares at a price of $7.57 per common share for a period of five years. These warrants were never issued and instead, on September 21, 2021, the Company granted compensation options (see below). On April 23, 2021, 1,948,000 escrowed share purchase warrants were exercised for $0.05 per share for gross proceeds of $97,400. On April 28, 2021, the Company issued 63,000 common shares to the University at a deemed price of $5.85 per share. The $368,550 value attributed to these shares has been recognized as a research and development expense in the consolidated statements of comprehensive loss during the year ended September 30, 2021. See Note 8. Issued share capital for the year ended September 30, 2020 On September 30, 2020, the Company closed the first tranche of a non-brokered private placement financing through the issuance of 623,941 common shares at a price $1.25 per common share for gross proceeds of $779,924. Special warrants and resulting share issuance In October 2020, the Company entered into subscription agreements for special warrants (the "SWs") whereby the subscribers subscribed for a total of 18,300 SWs at $1.25 per SW, with the SWs providing that each SW is deemed to be exercised, without payment of any additional consideration and without any further action by the SW holders, for one SW share, subject to adjustment in accordance with the provisions of the SW certificate on the SW exercise date. On November 2, 2020, the Company issued 18,300 SWs for gross proceeds of $22,875. On January 19, 2021, as a result of a compliance review of the SW offering by the British Columbia Securities Commission, the Company rescinded the issuance of 2,300 SWs and refunded the $2,875 in proceeds received. On February 3, 2021, the $20,000 in escrowed proceeds was released to the Company, the SWs were deemed to be exercised for SW shares and 16,000 common shares of the Company were issued to the SW holders. Escrowed securities On January 28, 2021, the Company entered into an escrow agreement under National Policy 46-201 Escrow for Initial Public Offerings • 480,080 on the date that the Company's shares are listed on the CSE (February 8, 2021); and • 720,120 6, 12, 18, 24, 30 and 36 months after the listing date. Stock options The Company's stock option plan provides for stock options to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the stock option plan, eligibility, vesting period, terms of the options and the number of options granted are to be determined by the Board of Directors at the time of grant. The stock option plan allows the Board of Directors to issue up to 10% of the Company's outstanding common shares as stock options. Options granted during the year ended September 30, 2022 On September 6, 2022, the Company granted 80,000 options to a director of the Company. These options have an exercise price of $2.46 per share, expire on September 6, 2027 and vest as follows: 25% on the grant date, 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 25% on the third anniversary of the grant date . The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $2.46; ii) share price: $2.40; iii) term: 5 years; iv) volatility: 147.31%; v) discount rate:3.33%; and dividends: nil. Options granted during the year ended September 30, 2021 On November 17, 2020, the Company granted 467,000 options, to the Chief Financial Officer of the Company, two directors of the Company and seven consultants. These options have an exercise price of $1.25 per share, expire on November 17, 2025 and vest as follows: • • • • The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $1.25; ii) share price: $1.25; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.43%; and dividends: nil. On April 28, 2021, the Company granted 240,000 options to three consultants of the Company. These options have an exercise price of $7.60 per share, expire on April 28, 2026 and vest as follows: • • The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.60; ii) share price: $5.98; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.92%; and dividends: nil. On June 15, 2021, the Company granted 180,000 options to a director and a consultant of the Company. These options have an exercise price of $7.60 per share, expire on June 15, 2026 and vest as follows: 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, 25% on the third anniversary of the grant date and 25% on the fourth anniversary of the grant date. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.60; ii) share price: $5.55; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.84%; and dividends: nil. On September 21, 2021, the Company granted 8,807 compensation options to a Finder (see above). These options have an exercise price of $7.64 per share, expire on September 21, 2024 and vest as follows: 25% on December 21, 2021, 25% on March 21, 2022, 25% on June 21, 2022 and 25% on September 21, 2022. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.64; ii) share price: $7.64; iii) term: 3 years; iv) volatility: 100%; v) discount rate: 0.55%; and dividends: nil. The following table summarizes the movements in the Company's outstanding stock options for years ended September 30, 2022, 2021 and 2020: Number of options Weighted average exercise price Balance at September 30, 2019 - - Granted 150,000 $ 1.25 Balance at September 30, 2020 150,000 $ 1.25 Granted 895,807 $ 4.29 Cancelled* (20,000 ) $ 1.25 Balance at September 30, 2021 1,025,807 $ 3.90 Granted 80,000 $ 2.46 Forfeited* (190,000 ) $ 4.59 Balance at September 30, 2022 915,807 $ 3.64 * On January 21, 2021, the Company cancelled 20,000 options granted to a consultant in error on November 17, 2020. Also, a consultant and a director forfeited their right to exercise 90,000 and 100,000 options respectively. As at September 30, 2022, the options have a weighted average remaining life of 3.39 years (September 30, 2021 - 4.28). The following table summarizes the stock options issued and outstanding: Options Outstanding and Exercisable Expiry Date Number of Exercisable Exercise price Remaining life September 21, 2024 8,807 8,807 $7.64 1.98 July 23, 2025 150,000 150,000 $1.25 2.81 November 17, 2025 357,000 122,333 $1.25 3.13 April 28, 2026 * 240,000 80,000 $7.60 3.58 June 15, 2026 80,000 20,000 $7.60 3.71 September 6, 2027 80,000 20,000 $2.46 4.94 * On December 1, 2022, the Company and a consultant mutually agreed to cancel 80,000 options (see Note 13). Restricted share unit plan The Company's restricted share unit ("RSU") plan provides RSUs to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the RSU plan, eligibility, vesting period, terms of the RSUs and the number of RSUs granted are to be determined by the Board of Directors at the time of the grant. The RSU plan allows the Board of Directors to issue common shares of the company as equity settled RSUs, provided that, when combined, the maximum number of common shares reserved for issuance under all share-based compensation arrangements of the Company does not exceed 10% of the Company's outstanding common shares. On February 4, 2022 and February 11, 2022, the Company issued 25,000 RSUs and 35,000 RSUs, respectively. These RSUs vest on an annual basis over a period of four years commencing on February 1, 2023. The estimated fair value of these RSUs is $181,250 and will be recognized as an expense over the vesting period of the RSUs. On April 27, 2022, the Company issued 100,000 RSUs to a director of the Company and these RSU's vest as follows: 25% on the date of grant and 25% each on April 27, 2024, 2025 and 2026. The estimated fair value of these RSUs is $127,000 and will be recognized as an expense over the vesting period of the RSUs. The following table summarizes the movements in the Company's outstanding RSUs for the years ended September 30, 2022 and 2021: Equity settled Cash settled Total Weighted average Balance at September 30, 2021 and 2020 380,000 - 380,000 $ 1.25 Granted 160,000 - 160,000 $ 5.91 Balance at September 30, 2022 540,000 - 540,000 $ 2.63 As at September 30, 2022, the RSUs have a weighted average remaining life of 3.38 years (September 30, 2021 - 3.91 years). The following table summarizes the RSUs issued and outstanding: RSUs Outstanding and Exercisable Expiry Date Number of RSUs Exercisable Exercise price Remaining life July 23, 2025 150,000 75,000 $ 1.25 2.81 September 18, 2025 230,000 115,000 $ 1.25 2.97 February 1, 2027 25,000 - $ 3.05 4.34 February 1, 2027 35,000 - $ 3.00 4.34 April 27, 2027 100,000 25,000 $ 7.64 4.58 Share-based compensation expense recognized in the consolidated statements of comprehensive loss is comprised of the following: For the year ended: September 30, 2022 September 30, September 30, $ $ $ Stock options 643,911 643,963 138,000 Restricted share units - equity settled grants 231,145 236,652 23,300 Total equity settled share-based compensation expense 875,056 880,615 161,300 Restricted share units - cash settled grants - - - Total share-based compensation expense 875,056 880,615 161,300 Share-based compensation expense is included in the consolidated statements of comprehensive loss as follows: For the years ended: September 30, 2022 September 30, September 30, $ $ $ Consulting fees 3,858 8,045 - Directors' compensation 99,438 136,612 - Marketing, advertising and investor relations - 3,696 - Professional fees - 23,126 - Research and development 771,760 709,136 161,300 Total share-based compensation expense 875,056 880,615 161,300 Warrants The following table summarizes the movements in the Company's outstanding warrants for the years ended September 30, 2022 and 2021: Number of warrants Weighted average exercise price Balance at September 30, 2020 4,079,600 $ 0.05 Issued* 1,709,938 9.46 Issued - broker 132,666 7.57 Exercised (1,948,000 ) 0.05 Balance at September 30, 2021 3,974,204 4.35 Issued 3,083,198 1.76 Issued - compensation warrants 225,198 1.40 Exercised (2,874,998 ) 0.68 Balance at September 30, 2022 4,407,602 $ 4.78 *On November 2, 2020, the Directors of the Company reduced the exercise price of the outstanding warrants from $0.125 to $0.05 effective July 11, 2020. On March 17, 2021, the Company issued 132,666 compensation warrants to underwriters. The fair value of these share purchase warrants of $521,000 was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.57; ii) share price: $6.65; iii) term: 3 years; iv) volatility: 100%; v) discount rate: 0.35%; and dividends: nil. The fair value of these broker warrants was recorded as a reduction against share capital. On August 30, 2022, the Company granted 225,198 compensation warrants at an exercise price of $1.40 per compensation warrant expiring on August 30, 2024. Each compensation warrant comprises the one Unit under the same terms of the offering which closed on August 30, 2022. The fair value of these compensation warrants of $315,000 was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $1.40; ii) share price: $2.93; iii) term: 2 years; iv) volatility: 147.31%; v) discount rate:3.63%; and dividends: nil. As at September 30, 2022, the warrants have a weighted average remaining life of 1.72 (September 30, 2021 - 2.66) years. The following table summarizes the warrants issued and outstanding: Warrants Outstanding Expiry Date Number of Exercise price Remaining life July 30, 2024 (1) 314,800 $ 0.05 1.83 March 17, 2024 1,697,438 $ 9.46 1.46 March 17, 2024 132,666 $ 7.57 1.46 August 30, 2024 2,037,500 $ 1.76 1.92 August 30, 2024 134,040 $ 1.76 1.92 August 30, 2024 91,158 $ 1.76 1.92 (1) On June 15, 2021, the Company entered into warrant exercise agreements with the two warrant holders, whereby the warrant holders authorized the Company to issue only such number of common shares (or other class of voting securities of the Company, if applicable) as will result in the warrant holders and any other person (as defined) holding less than the threshold number of 4.99% (as defined) of any class of voting securities of the Company as of the date of exercise or conversion of the warrants.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Sep. 30, 2022
Disclosure of transactions between related parties [abstract]
RELATED PARTY TRANSACTIONS [Text Block]	7. RELATED PARTY TRANSACTIONS Related party transactions were recorded at the exchange value, which is the consideration determined and agreed to by the related parties. The Company's related parties include directors, key management and companies controlled by directors and key management. Included in accounts payable and accrued liabilities as at September 30, 2022 was $105,181 (September 30, 2021 - $ Nil Compensation of Key Management Personnel Key management personnel are those persons that have authority and responsibility for planning, directing and controlling the activities of the Company, directly and indirectly, and by definition include the directors of the Company. The following table summarizes expenses related to key management personnel: For the year ended: September 30, 2022 September 30, 2021 September 30, 2020 $ $ $ Professional fees 144,000 87,074 22,575 Research and development 572,700 772,596 26,777 Consulting fees 174,215 - - Share-based compensation included in directors' compensation 99,438 136,612 - Share-based compensation included in professional fees - 23,126 - Share-based compensation included in research and development 123,052 236,652 161,300 1,113,405 1,256,060 210,652 See Note 8 for related party contractual obligations.

CONTRACTUAL OBLIGATIONS

CONTRACTUAL OBLIGATIONS	12 Months Ended
	Sep. 30, 2022
Disclosure Of Contractual Obligation [Abstract]
CONTRACTUAL OBLIGATIONS [Text Block]	8. CONTRACTUAL OBLIGATIONS License agreement On April 23, 2021, the Company entered into an exclusive license agreement with equity (the "LA") with the Board of Trustees of the UIC (the "University") whereby the University granted to the Company, in all fields of use and worldwide, an exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Patent Rights (as defined) and a non-exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Technical Information (as defined) to make, have made, construct, have constructed, use, import, sell, and offer for sale royalty-bearing Product (as defined). As consideration for the grant of license, the Company will pay the following amounts (in US$) to the University: Signing Fee Net Sales Sublicensee Revenues - Annual Minimums - Years 1 and 2 - $ nil Year 3 - $5,000; Year 4 - $15,000; Year 5 - $35,000; Year 6 and thereafter - $50,000; and After first commercial sale - $250,000 or net sales royalty, whichever is higher. Milestone Payments - Prior to any sublicensing agreements, joint ventures or change of control $10,000 upon dosing the first patient in a Phase I trial; $50,000 upon dosing the first patient in the first Phase II trial; $250,000 upon dosing the first patient in a Phase III trial in the first clinical indication; and $2 million upon the first commercial sale of each clinical indication. After any sublicensing agreements, joint ventures or change of control As above; $250,000 upon dosing the first patient in each Phase II trial; $500,000 upon dosing the first patient in each Phase III trial; and $2 million upon the first commercial sale of each clinical indication. Unless otherwise agreed to in writing by the University, the Company will reimburse the University for all documented costs and expenses in connection with the Patent Rights, including the preparation, filing, prosecution, maintenance and defense thereof. From time to time, the anticipated costs and expenses may be significant and, upon request, the Company will pay the estimated costs and expenses in advance of such costs and expenses being incurred by the University. The term of the LA ends on the later of the last to expire of the Patent Rights, expiration of regulatory exclusivity for Product or when the Company provides notice that use of Technical Information has ceased. The University has the right to terminate the LA if the Company fails to make any required payments or is in breach of any provision of the LA. The Company may terminate the LA at any time upon providing at least 90 days written notice to the University. Related party contracts On June 5, 2020, the Company entered into an independent consultant agreement (the "ICA") whereby the consultant, a private corporation incorporated in the State of California, USA, was engaged and the consultant's representative will serve as the Company's Chief Medical Officer, with the services being provided in California. As compensation for performing these services, the consultant or the consultant's representative will participate in the Company's equity incentive plans and will be eligible for cash payments in respect of fees at such time as the Company begins to compensate other C-level personnel in cash and in similar proportion to total compensation (the "fees"). The non-cash portion of the consultant's fees was in the form of a grant of 150,000 vested stock options and 380,000 RSUs (see Note 6). The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by either party giving the other 30 days written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless either party gives the other 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000 and increased it to US$25,000 in August 2021. The Chief Medical Officer's engagement was terminated effective November 23, 2022 and 190,000 of the unvested RSUs were cancelled. On October 29, 2020, the Company entered into an independent contractor agreement (the "ICA") whereby the contractor was engaged to serve as the Company's Chief Science Officer on an as-needed basis. The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000 and increased it to US$25,000 in August 2021. Services provided by the Chief Science Officer ceased at the end of March 2022 and no further payments were made or due by the Company from April 2022 onwards. The Chief Science Officer later resigned at the end of June 2022. In November 2021, April 2022 and September 2022, the Company entered into director indemnity agreements (the "DIAs") with seven directors (two of these directors has resigned to date) of the Company. Pursuant to the DIAs and subject to all applicable laws, including the applicable limitations and restrictions set forth in the Business Corporations Act (British Columbia), the Company will: Indemnify and save harmless the Directors against and from: any and all charges or claims by reason of them being or having been a director of the Company or another corporation, at a time when the other corporation is or was an affiliate of the Company, or at the request of the Company; any and all costs, damages, expenses, fines, liabilities, losses and penalties (the "Consequences") which they may sustain, incur or be liable for in consequence of their acting as a director of the Company, whether sustained or incurred by reason of their negligence, default, breach of duty or trust, failure to exercise due diligence or otherwise in relation to the Company or any of its affairs; and in particular, and without in any way limiting the generality of the foregoing, any and all Consequences which they may sustain, incur or be liable for as a result of or in connection with the release or presence in the environment of substances, contaminants, litter, waste, effluent, refuse, pollutants or deleterious materials and that arise out of or are in any way connected with the management, operation, activities or existence of the Company or by virtue of them holding any other directorship with any other entity at the Company's request. gross up any indemnity payment made pursuant to the DIAs by the amount of any income tax payable by the Directors in respect of that payment; and indemnify the Directors for the amount of all costs they incur in obtaining any Court approval required to enable or require the Company to make a payment to them under the DIAs, or enforce the DIAs against the Company, including without limitation legal fees and disbursements on a full indemnity basis. Notwithstanding the above-noted, the Company will have no obligation to indemnify or save harmless the Directors in respect of any liability for which they are entitled to indemnity pursuant to any valid and collectible policy of insurance obtained and maintained by the Company, to the extent of the amounts actually collected by the Directors under the insurance policy. On April 11, 2022, the Company entered into a scientific advisory board agreement with Karl Deisseroth ("Deisseroth") pursuant to which the Company will pay Deisseroth a monthly fee of US$4,167 and issued an aggregate 25,000 common shares (the "Payment Shares") in the capital of the Company (see Note 6). Scientific advisory board agreements The Company entered into numerous scientific advisory board agreements (the "SABAs") whereby the advisors were retained to serve as members of the Company's scientific advisory board and as consultants to the Company and senior management in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates of $150 and $160 per hour. The Company also granted 130,000 stock options to the advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options of which 20,000 options were cancelled on January 21, 2021 (see Note 6). In addition, the Company granted 60,000 RSU's to the advisors of the Company on February 4, 2022 and February 11, 2022 (see Note 6). The advisors have the same hour requirements and restrictions as noted below. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the SABAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice. Consulting agreements The Company has entered into numerous consulting agreements (the "CAs") whereby the consultants were retained to serve as advisors to the Company and senior management in the areas of public relations and content creation and scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates between US$30 to US$600. The Company also granted 302,000 stock options to six advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options (see Note 6). The advisors being paid $400 and $600 per hour will reserve at least six full days of services to the Company and such additional days as requested by the Company each annual period, but not to exceed 36 full days of service per year unless otherwise agreed and up to a maximum of 288 hours total per year, unless otherwise agreed. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the CAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice. On October 9, 2020, the Company entered into a CA whereby the consultant was retained to serve as an advisor to the Company in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisor an hourly rate of US$130. The Company granted 90,000 stock options to the consultant on November 17, 2020 (see Note 6). On November 6, 2020, the Company entered into a sponsored research agreement (the "SRA") with the University of Texas Medical Branch (the "UTMB") whereby the UTMB conducted a research program on behalf of the Company. Pursuant to the SRA, the agreement is effective as of October 15, 2020 and the research program was carried out through to its conclusion on February 15, 2021. As consideration for UTMB's performance, the Company paid US$66,764 which was recorded in research and development costs. On November 17, 2020, the Company entered into an ICA whereby the contractor was engaged to serve as the Company's Vice President (Discovery). The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000. On November 1, 2021, the Company entered into a letter agreement (the "LA") with a New York-based company, whereby the company will provide investor relations services to the Company. As compensation for performing these services, the Company will pay a non-refundable monthly retainer of US$5,000 and issue 11,200 shares of restricted stock in three tranches: 3,800 on January 1, 2022; 3,700 on April 1, 2022 and 3,700 on July 1, 2022. If the contract is terminated prior to the issuance date, the outstanding balance is not owed. The services will continue for an initial term of one year unless sooner terminated by either party giving the other 15 days written notice.

FINANCIAL INSTRUMENTS AND CAPIT

FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT	12 Months Ended
	Sep. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT [Text Block]	9. FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT The following table summarizes the carrying value of financial assets and liabilities: September 30, 2022 September 30, 2021 FVTPL $ $ Cash 11,541,663 19,673,765 Guaranteed investment certificate 86,250 86,250 Cash and cash equivalents 11,627,913 19,760,015 Amortized cost Accounts payable and accrued liabilities 1,404,561 638,573 Fair value measurement Financial assets and liabilities that are recognized on the consolidated statement of financial position at fair value can be classified in a hierarchy that is based on the significance of the inputs used in making the measurements. The levels in the hierarchy are: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices); and Level 3 - inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs). The Company's cash and cash equivalents is classified as Level 1, whereas accounts payable and accrued liabilities are classified as Level 2. As at September 30, 2022, the Company believes that the carrying values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values because of their nature and relatively short maturity dates or durations. Financial risk management The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes. The type of risk exposure and the way in which such exposure is managed is provided as follows: Credit risk Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash and cash equivalents balance. As at September 30, 2022, the Company had cash and cash equivalents of $11,627,913 which was held with major banks in Canada, United States and Australia. Because deposits are with three banks, there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments. The credit risk is assessed as low. Foreign exchange risk Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As at September 30, 2022, the Company had the following foreign currency balances - cash (US$862,731 and AU$27,123), receivables (US$30,102 and AU$42,000), prepaids (US$116,276 and AU$13,417) and accounts payable and accrued liabilities (US$785,439 and AU$215,218). A 10% fluctuation in the US$ and AU$ against the Canadian dollar would have an impact of approximately $19,000 on the net comprehensive loss. Liquidity risk Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time. The Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. As at September 30, 2022, the Company had cash and cash equivalents of $11,627,913 to cover current liabilities of $1,472,489. Capital management Management's objective is to manage its capital to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern through the optimization of its capital structure. The capital structure consists of share capital and working capital. In order to achieve this objective, management makes adjustments to it in light of changes in economic conditions and risk characteristics of the underlying assets. To maintain or adjust the capital structure, management may invest its excess cash in interest bearing accounts of Canadian chartered banks and/or raise additional funds externally as needed. The Company is not subject to externally imposed capital requirements. The Company's management of capital did not change during the year ended September 30, 2022.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	12 Months Ended
	Sep. 30, 2022
Research And Development [Abstract]
RESEARCH AND DEVELOPMENT [Text Block]	10. RESEARCH AND DEVELOPMENT Research and development expense recognized in the consolidated statements of comprehensive loss is comprised of the following: For the year ended: September 30, 2022 September 30, September 30, $ $ $ Laboratory costs (see Note 11) 146,649 82,871 25,874 Novel drug development 8,557,000 3,638,910 110,029 Patents and related payments 73,645 513,302 13,895 Salary and subcontractors 2,631,884 1,369,769 43,754 Share-based compensation (see Note 6) 771,760 709,136 161,300 12,180,938 6,313,988 354,852

PREMISES LEASES

PREMISES LEASES	12 Months Ended
	Sep. 30, 2022
Presentation of leases for lessee [abstract]
PREMISES LEASES [Text Block]	11. PREMISES LEASES Commencing June 1, 2021, the Company entered into a commercial laboratory lease in Wauwatosa, Wisconsin USA for a term of one year at a monthly base rent of US$1,709. For the period ended September 30, 2022, $18,673 is included in laboratory costs (see Note 10). Commencing September 1, 2021, the Company entered into an apartment lease in New York, New York USA for a term of one year at a monthly base rent of US$5,300. For the year ended September 30, 2022, $73,700 is included in office and administrative expense. Commencing September 1, 2022, the Company extended the lease for a term of two years at a monthly base rent of US$5,510 for the first year and US$5,630 for the second year of the lease. (a) As at September 30, 2022, $138,863 of right-of-use assets are recorded as follows: 2022 As at September 30, 2021 $ - Inception of lease 144,900 Depreciation (6,037 ) As at September 30, 2022 $ 138,863 (b) Minimum lease payments in respect of lease liabilities and the effect of discounting are as follows: 2022 Undiscounted minimum lease payments: Less than one year $ 86,112 Two to three years 80,509 166,621 Effect of discounting (26,710 ) Present value of minimum lease payments 139,911 Less current portion (67,928 ) Long-term portion $ 71,983 (c) Lease Liability Continuity The lease liability continuity is as follows: 2022 As at September 30, 2021 $ - Inception of lease 144,900 Cash flows: Principal payments (4,989 ) As at September 30, 2022 $ 139,911 During the year ended September 30, 2022, interest of $2,173 is included in the office and administrative expense on the consolidated statements of comprehensive loss.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2022
Major components of tax expense (income) [abstract]
INCOME TAXES [Text Block]	12. A reconciliation of the expected income tax recovery to the actual income tax recovery is as follows: September 30, 2022 September 30, September 30, $ $ $ Net loss (14,964,941 ) (8,650,763 ) (480,377 ) Statutory tax rate 27.26% 27.75% 27% Expected income tax recovery (4,079,645 ) (2,400,311 ) (129,702 ) Deductible and non-deductible items 21,093 (256,939 ) 42,136 Change in deferred tax assets not recognized 4,058,552 2,657,250 87,566 Total income tax recovery - - - The Company has the following deductible temporary differences for which no deferred tax has been recognized: September 30, 2022 September 30, $ $ Non-capital losses 23,360,000 9,976,000 Share issue costs 1,726,000 1,448,000 Intangible assets - (1,000 ) Valuation allowance (25,086,000 ) (11,423,000 ) Net deferred income tax assets - - The Company has Canadian non-capital losses of approximately $21,545,000 (2021 - $9,940,000), US non-capital losses of $ 188,000 (2021 - $30,000) and Australian non-capital losses of $1,627,000 (2021- $7,000), which may be carried forward and applied against taxable income in future years. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements and have been offset by a valuation allowance. The Company's Canadian non-capital loss carry-forwards expire as follows: Year of Origin Year of Expiry Non-Capital Losses $ 2019 2039 42,000 2020 2040 298,000 2021 2041 8,133,000 2022 2042 14,887,000 23,360,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Sep. 30, 2022
Disclosure of non-adjusting events after reporting period [abstract]
SUBSEQUENT EVENTS [Text Block]	13. On November 13, 2022, the Company entered into an ICA whereby the contractor was engaged to serve as the Chief Medical Officer of the Company effective December 1, 2022. The Company agreed to pay a signing bonus of US$35,000 upon the execution of the ICA and a fee of US$205,000 annually, payable in monthly installments. The Company also agreed to reimburse for reasonable and approved expenses arising in connection with the performance of the services. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing one month written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In connection with the ICA, the Company granted 300,000 options with an exercise price of $1.65 per share, expire on December 1, 2027 and vest as follows: 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, 25% on the third anniversary of the grant date, and 25% on the fourth anniversary of the grant date. On December 1, 2022, the Company issued 1,100,000 RSUs to the directors of the Company. These RSUs vest on an annual basis over a period of four years commencing on December 1, 2022 and expiring on December 1, 2027. On December 1, 2022, the Company and a consultant mutually agreed to cancel 80,000 options that were previously granted on April 28, 2021 (see Note 6). On December 2, 2022, the Company closed a non-brokered private placement of 666,000 pre-funded warrants ("PFWs") of the Company at a price of $1.249 per PFW and 974,000 Units of the Company at a price of $1.25 per Unit for aggregate gross proceeds of $2,049,334. Each PFW is exercisable into one Unit at an exercise price of $0.001 per Unit on the date that is the earlier of (a) the date the holder thereof elects to exercise the PFWs and pays the exercise price, and (b) December 2, 2024. Each Unit is comprised of one common share and one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company at an exercise price of $1.35 per share until December 2, 2024. Subsequent to September 30, 2022, an aggregate of 144,000 warrants were exercised for gross proceeds of $253,440.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Sep. 30, 2022
Disclosure Of Detailed Information About Significant Accounting Policies [Abstract]
Basis of consolidation [Policy Text Block]	Basis of consolidation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021. On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company. A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated. Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these consolidated financial statements.
Critical accounting estimates [Policy Text Block]	Critical accounting estimates The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these consolidated financial statements. Ability to continue as a going concern Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments. Share-based compensation The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date. The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur.
Foreign currency translation [Policy Text Block]	Foreign currency translation The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss.
Business combinations [Policy Text Block]	Business combinations The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss. Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses. Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.
Internally generated intangible assets - Research and development expenditure [Policy Text Block]	Internally generated intangible assets - Research and development expenditure Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: • The technical feasibility of completing the intangible asset so that it will be available for use or sale; • The intention to complete the intangible asset and use or sell it; • The ability to use or sell the intangible asset; • How the intangible asset will generate probable future economic benefits; • The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and • The ability to measure reliably the expenditure attributable to the intangible asset during its development. The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred. Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately. At September 30, 2022 and 2021, the Company has not recognized any internally-generated intangible assets.
Share-based compensation awards [Policy Text Block]	Share-based compensation awards Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital. For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout.
Provisions [Policy Text Block]	Provisions A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss.
Income taxes [Policy Text Block]	Income taxes Current income tax: Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income. Deferred tax: Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.
Loss per share [Policy Text Block]	Loss per share Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share.
Share capital [Policy Text Block]	Share capital Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments. Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax.
Financial instruments [Policy Text Block]	Financial instruments Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets (a) Recognition and measurement of financial assets The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument. (b) Classification of financial assets The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL"). (i) Financial assets measured at amortized cost A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost: • The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows. • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding. A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary. (ii) Financial assets measured at FVTOCI A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss. (iii) Financial assets measured at FVTPL A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises. The Company's cash and cash equivalents are classified as subsequently measured at FVTPL. (c) Derecognition of financial assets The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the consolidated statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss. Financial liabilities (a) Recognition and measurement of financial liabilities The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument. (b) Classification of financial liabilities (i) Financial liabilities measured at amortized cost A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method. The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost. (ii) Financial liabilities measured at fair value through profit or loss A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises. (c) Derecognition of financial liabilities The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the consolidated statement of comprehensive loss. Offsetting financial assets and liabilities Financial assets and liabilities are offset and the net amount is presented in the consolidated statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Impairment of financial assets The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit losses. The Company recognizes in the consolidated statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.
Leases [Policy Text Block]	Leases Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration. The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset. As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. Right-of-use asset The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received. The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset. In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability. Lease liability A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method.
New standards and interpretations not yet adopted [Policy Text Block]	New standards and interpretations not yet adopted A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2022 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future: IAS 1 - Presentation of Financial Statements An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period. IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor." IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors IAS 8 amended the definition of material reflect the changes outlined above under IAS 1. IAS 12 and IFRIC 23 - Income Taxes IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Sep. 30, 2022
Trade and other current payables [abstract]
Disclosure of accounts payable and accrued liabilities [Table Text Block]	September 30, 2022 September 30, 2021 $ $ Accounts payable 1,246,384 596,573 Accrued liabilities 158,177 42,000 Total accounts payable and accrued liabilities 1,404,561 638,573

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	12 Months Ended
	Sep. 30, 2022
Disclosure of classes of share capital [abstract]
Disclosure of number and weighted average exercise prices of share options [Table Text Block]	Number of options Weighted average exercise price Balance at September 30, 2019 - - Granted 150,000 $ 1.25 Balance at September 30, 2020 150,000 $ 1.25 Granted 895,807 $ 4.29 Cancelled* (20,000 ) $ 1.25 Balance at September 30, 2021 1,025,807 $ 3.90 Granted 80,000 $ 2.46 Forfeited* (190,000 ) $ 4.59 Balance at September 30, 2022 915,807 $ 3.64
Disclosure of number of issued and outstanding stock options [Table Text Block]	Options Outstanding and Exercisable Expiry Date Number of Exercisable Exercise price Remaining life September 21, 2024 8,807 8,807 $7.64 1.98 July 23, 2025 150,000 150,000 $1.25 2.81 November 17, 2025 357,000 122,333 $1.25 3.13 April 28, 2026 * 240,000 80,000 $7.60 3.58 June 15, 2026 80,000 20,000 $7.60 3.71 September 6, 2027 80,000 20,000 $2.46 4.94
Disclosure of number and weighted average exercise prices of restricted share units [Table Text Block]	Equity settled Cash settled Total Weighted average Balance at September 30, 2021 and 2020 380,000 - 380,000 $ 1.25 Granted 160,000 - 160,000 $ 5.91 Balance at September 30, 2022 540,000 - 540,000 $ 2.63
Disclosure of number of outstanding and exercisable restricted share units [Table Text Block]	RSUs Outstanding and Exercisable Expiry Date Number of RSUs Exercisable Exercise price Remaining life July 23, 2025 150,000 75,000 $ 1.25 2.81 September 18, 2025 230,000 115,000 $ 1.25 2.97 February 1, 2027 25,000 - $ 3.05 4.34 February 1, 2027 35,000 - $ 3.00 4.34 April 27, 2027 100,000 25,000 $ 7.64 4.58
Disclosure of share based payments recognized in the consolidated statements of comprehensive loss [Table Text Block]	For the year ended: September 30, 2022 September 30, September 30, $ $ $ Stock options 643,911 643,963 138,000 Restricted share units - equity settled grants 231,145 236,652 23,300 Total equity settled share-based compensation expense 875,056 880,615 161,300 Restricted share units - cash settled grants - - - Total share-based compensation expense 875,056 880,615 161,300
Disclosure of share based payments included in the consolidated statements of comprehensive loss [Table Text Block]	For the years ended: September 30, 2022 September 30, September 30, $ $ $ Consulting fees 3,858 8,045 - Directors' compensation 99,438 136,612 - Marketing, advertising and investor relations - 3,696 - Professional fees - 23,126 - Research and development 771,760 709,136 161,300 Total share-based compensation expense 875,056 880,615 161,300
Disclosure of number and weighted average exercise prices of warrants [Table Text Block]	Number of warrants Weighted average exercise price Balance at September 30, 2020 4,079,600 $ 0.05 Issued* 1,709,938 9.46 Issued - broker 132,666 7.57 Exercised (1,948,000 ) 0.05 Balance at September 30, 2021 3,974,204 4.35 Issued 3,083,198 1.76 Issued - compensation warrants 225,198 1.40 Exercised (2,874,998 ) 0.68 Balance at September 30, 2022 4,407,602 $ 4.78
Disclosure of number of outstanding warrants [Table Text Block]	Warrants Outstanding Expiry Date Number of Exercise price Remaining life July 30, 2024 (1) 314,800 $ 0.05 1.83 March 17, 2024 1,697,438 $ 9.46 1.46 March 17, 2024 132,666 $ 7.57 1.46 August 30, 2024 2,037,500 $ 1.76 1.92 August 30, 2024 134,040 $ 1.76 1.92 August 30, 2024 91,158 $ 1.76 1.92

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Sep. 30, 2022
Disclosure of transactions between related parties [abstract]
Disclosure of expenses related to key management personnel [Table Text Block]	For the year ended: September 30, 2022 September 30, 2021 September 30, 2020 $ $ $ Professional fees 144,000 87,074 22,575 Research and development 572,700 772,596 26,777 Consulting fees 174,215 - - Share-based compensation included in directors' compensation 99,438 136,612 - Share-based compensation included in professional fees - 23,126 - Share-based compensation included in research and development 123,052 236,652 161,300 1,113,405 1,256,060 210,652

FINANCIAL INSTRUMENTS AND CAP_2

FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)	12 Months Ended
	Sep. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
Disclosure of carrying value of financial assets and liabilities [Table Text Block]	September 30, 2022 September 30, 2021 FVTPL $ $ Cash 11,541,663 19,673,765 Guaranteed investment certificate 86,250 86,250 Cash and cash equivalents 11,627,913 19,760,015 Amortized cost Accounts payable and accrued liabilities 1,404,561 638,573

RESEARCH AND DEVELOPMENT (Table

RESEARCH AND DEVELOPMENT (Tables)	12 Months Ended
	Sep. 30, 2022
Research And Development [Abstract]
Disclosure of research and development expenses [Table Text Block]	For the year ended: September 30, 2022 September 30, September 30, $ $ $ Laboratory costs (see Note 11) 146,649 82,871 25,874 Novel drug development 8,557,000 3,638,910 110,029 Patents and related payments 73,645 513,302 13,895 Salary and subcontractors 2,631,884 1,369,769 43,754 Share-based compensation (see Note 6) 771,760 709,136 161,300 12,180,938 6,313,988 354,852

PREMISES LEASES (Tables)

PREMISES LEASES (Tables)	12 Months Ended
	Sep. 30, 2022
Presentation of leases for lessee [abstract]
Disclosure of right-of-use assets [Table Text Block]	2022 As at September 30, 2021 $ - Inception of lease 144,900 Depreciation (6,037 ) As at September 30, 2022 $ 138,863
Disclosure of minimum lease payments in respect of lease liabilities [Table Text Block]	2022 Undiscounted minimum lease payments: Less than one year $ 86,112 Two to three years 80,509 166,621 Effect of discounting (26,710 ) Present value of minimum lease payments 139,911 Less current portion (67,928 ) Long-term portion $ 71,983
Disclosure of lease liability continuity [Table Text Block]	2022 As at September 30, 2021 $ - Inception of lease 144,900 Cash flows: Principal payments (4,989 ) As at September 30, 2022 $ 139,911

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2022
Major components of tax expense (income) [abstract]
Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery [Table Text Block]	September 30, 2022 September 30, September 30, $ $ $ Net loss (14,964,941 ) (8,650,763 ) (480,377 ) Statutory tax rate 27.26% 27.75% 27% Expected income tax recovery (4,079,645 ) (2,400,311 ) (129,702 ) Deductible and non-deductible items 21,093 (256,939 ) 42,136 Change in deferred tax assets not recognized 4,058,552 2,657,250 87,566 Total income tax recovery - - -
Disclosure of deductible temporary differences for which no deferred tax has been recognized [Table Text Block]	September 30, 2022 September 30, $ $ Non-capital losses 23,360,000 9,976,000 Share issue costs 1,726,000 1,448,000 Intangible assets - (1,000 ) Valuation allowance (25,086,000 ) (11,423,000 ) Net deferred income tax assets - -
Disclosure of non-capital loss carry-forwards expiry [Table Text Block]	Year of Origin Year of Expiry Non-Capital Losses $ 2019 2039 42,000 2020 2040 298,000 2021 2041 8,133,000 2022 2042 14,887,000 23,360,000

NATURE AND CONTINUANCE OF OPE_2

NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details) - CAD ($)		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Nature And Continuance Of Operations [Abstract]
Net loss	$ (14,964,941)	$ (14,964,941)	$ (8,650,763)	$ (480,377)
Deficit	(9,209,857)	(24,174,798)	(9,209,857)
Working capital	$ 19,399,795	$ 10,475,632	$ 19,399,795

INTANGIBLE ASSETS (Narrative)

INTANGIBLE ASSETS (Narrative) (Details) - PsilocybinLabs Ltd [Member]	Aug. 07, 2019 CAD ($) Shares shares	Apr. 25, 2019 CAD ($) shares
Share Exchange And Assignment [Line Items]
Number of shares issued by PL to individual | shares		100,000
Value of common stock issued by PL to individual | $		$ 2,000
Common shares purchased | shares	100,000
Number of shares issued | Shares	100,000
Value of common stock shares issued | $	$ 2,000

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details) - CAD ($)	Sep. 30, 2022	Sep. 30, 2021
Trade and other current payables [abstract]
Accounts payable	$ 1,246,384	$ 596,573
Accrued liabilities	158,177	42,000
Total accounts payable and accrued liabilities	$ 1,404,561	$ 638,573

SHARE CAPITAL (Narrative) (Deta

SHARE CAPITAL (Narrative) (Details)

1 Months Ended

12 Months Ended

Dec. 01, 2022 Shares shares

Sep. 06, 2022 shares Year $ / shares

Apr. 11, 2022 CAD ($) $ / shares shares

Apr. 11, 2022 USD ($) shares

Feb. 11, 2022 CAD ($)

Apr. 06, 2021 CAD ($) $ / shares shares

Feb. 03, 2021 CAD ($) shares

Jan. 06, 2021 CAD ($) $ / shares shares

Nov. 10, 2020

Nov. 02, 2020 CAD ($) $ / shares shares

Aug. 30, 2022 CAD ($) Year $ / shares $ / Shares shares

Apr. 27, 2022 CAD ($)

Sep. 21, 2021 shares Year $ / shares

Jun. 15, 2021 shares Year $ / shares

Apr. 28, 2021 CAD ($) shares Year $ / shares

Apr. 23, 2021 CAD ($) $ / shares shares

Mar. 17, 2021 CAD ($) Year $ / shares $ / Shares shares

Jan. 28, 2021 shares

Jan. 21, 2021 Shares

Jan. 19, 2021 CAD ($) shares

Nov. 17, 2020 shares Year $ / shares

Oct. 31, 2020 $ / shares shares

Sep. 30, 2020 CAD ($) $ / shares shares

Sep. 30, 2022 CAD ($) shares $ / shares

Sep. 30, 2021 CAD ($) shares $ / shares

Sep. 30, 2020 shares $ / shares

Feb. 04, 2022 CAD ($)

Nov. 01, 2020 $ / shares

Disclosure of classes of share capital [line items]

Description of issued and outstanding common shares

On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis.

Shares issued to a consultant | $

$ 27,250

Number of units issued

2,858,000

3,419,883

Units issued, price per unit | $ / Shares

1.4

7.57

Gross proceeds from units issued | $

$ 4,001,200

$ 25,888,514

Exercise price, warrants granted | $ / shares

$ 1.76

$ 9.46

Underwriters fees paid | $

$ 280,084

$ 916,317

Underwriters expenses | $

176,065

Share issue costs | $

84,585

Minimum daily volume weighted average trading share price on the CSE | $ / shares

$ 13.25

Shares issued to the University (shares)

63,000

Shares issued to the University | $

$ 368,550

$ 368,550

Shares issued price per share | $ / shares

$ 5.85

Proceeds from share subscriptions | $

$ 33,684

Karl Deisseroth Agreement [Member]

Disclosure of classes of share capital [line items]

Deisseroth monthly fee | $

$ 4,166.66

Shares issued to a consultant (shares)

25,000

25,000

Shares issued to a consultant | $

$ 27,250

Shares issued price per share | $ / shares

$ 1.09

Escrow Agreement [Member]

Disclosure of classes of share capital [line items]

Number of common shares deposited to be held in escrow

2,852,800

Number of warrants deposited to be held in escrow

1,948,000

Aggregate securities deposited to be held in escrow

4,800,800

Escrowed securities to be released once shares are listed on Canadian Stock Exchange

480,080

Escrowed securities to be released after listing date

720,120

Subsequent events [Member]

Disclosure of classes of share capital [line items]

Number of warrants exercised

144,000

Gross proceeds from warrants exercised | $

$ 253,440

Advisor [Member]

Disclosure of classes of share capital [line items]

Underwriters fees paid | $

$ 259,245

Consultant [Member] | Debt Settlement Agreement [Member]

Disclosure of classes of share capital [line items]

Number of shares issued during period

14,799

Debt settled through issuance of shares | $

$ 18,500

Shares issued price per share | $ / shares

$ 1.25

Consultant [Member] | Subsequent events [Member]

Disclosure of classes of share capital [line items]

Number of options cancelled | Shares

80,000

Three Investors [Member]

Disclosure of classes of share capital [line items]

Proceeds from issue of ordinary shares | $

$ 13,333,333

Contingent cash fee | $

$ 600,000

Percentage of equity proceeds received from three investors

4.50%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options One [Member]

Disclosure of classes of share capital [line items]

Number of options granted

25,000

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options One [Member] | On the date of grant [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

100%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member]

Disclosure of classes of share capital [line items]

Number of options granted

14,000

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the Company's listing date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the first anniversary of the listing date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the second anniversary of the listing date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

50%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member]

Disclosure of classes of share capital [line items]

Number of options granted

4,000

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] | On the Company's listing date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

50%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] | On the six-month anniversary of the listing date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

50%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member]

Disclosure of classes of share capital [line items]

Number of options granted

424,000

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the first anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

33%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the second anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

33%

Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the third anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

33%

Three Consultants [Member] | Stock Options One [Member]

Disclosure of classes of share capital [line items]

Number of options granted

160,000

Three Consultants [Member] | Stock Options One [Member] | On the first anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options One [Member] | On the second anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options One [Member] | On the third anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options One [Member] | On the fourth anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options Two [Member]

Disclosure of classes of share capital [line items]

Number of options granted

80,000

Three Consultants [Member] | Stock Options Two [Member] | On the six-month anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options Two [Member] | On the first anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options Two [Member] | On the second anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Three Consultants [Member] | Stock Options Two [Member] | On the eighteen-month anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Warrants [Member]

Disclosure of classes of share capital [line items]

Issued - compensation warrants

225,198

Number of warrants, Issued

134,040

3,083,198

1,709,938

Exercise price, warrants granted | $ / shares

$ 1.4

Weighted average exercise price of warrants issued | $ / shares

$ 1.76

$ 9.46

Warrants exercise price | $ / shares

$ 0.05

$ 0.05

$ 4.78

$ 4.35

$ 0.05

$ 0.125

Number of warrants exercised

2,874,998

1,948,000

Warrants exercised (shares)

2,649,800

Weighted average exercise price, Exercised | $ / shares

$ 0.68

$ 0.05

Gross proceeds from warrants exercised | $

$ 1,653,170

Weighted average remaining contractual life of outstanding warrants

1 year 8 months 19 days

2 years 7 months 28 days

Threshold percentage of warrants

4.99%

Warrants [Member] | Warrant exercise price one [Member]

Disclosure of classes of share capital [line items]

Weighted average exercise price, Exercised | $ / shares

$ 0.05

Warrants [Member] | Warrant exercise price two [Member]

Disclosure of classes of share capital [line items]

Weighted average exercise price, Exercised | $ / shares

1.76

Warrants [Member] | Warrant exercise price three [Member]

Disclosure of classes of share capital [line items]

Weighted average exercise price, Exercised | $ / shares

$ 9.46

Compensation warrants [Member]

Disclosure of classes of share capital [line items]

Proceeds from exercise of warrants | $

$ 315,277

Reserves to share capital | $

$ 531,000

Number of warrants, Issued

8,807

225,198

Exercise price, warrants granted | $ / shares

$ 7.57

$ 1.4

Number of warrants exercised

225,198

Term of warrant

5 years

Fair value of share purchase warrants

315,000

Share price, warrants granted | $ / shares

$ 2.93

Estimated life, warrants granted | Year

2

Expected volatility, warrants granted

147.31%

Discount rate, warrants granted

3.63%

Compensation warrants [Member] | Advisor [Member]

Disclosure of classes of share capital [line items]

Number of warrants, Issued

91,158

Exercise price, warrants granted | $ / shares

$ 1.4

Compensation warrants [Member] | Underwriters [Member]

Disclosure of classes of share capital [line items]

Number of warrants, Issued

132,666

Exercise price, warrants granted | $ / shares

$ 7.57

Warrant ascribed value | $

$ 521,000

Fair value of share purchase warrants

521,000

Share price, warrants granted | $ / shares

$ 6.65

Estimated life, warrants granted | Year

3

Expected volatility, warrants granted

100%

Discount rate, warrants granted

0.35%

Second tranche of a non-brokered private placement [Member]

Disclosure of classes of share capital [line items]

Number of shares issued during period

1,629,138

Proceeds from issue of ordinary shares | $

$ 2,036,422

Shares issued price per share | $ / shares

$ 1.25

First tranche of a non-brokered private placement [Member]

Disclosure of classes of share capital [line items]

Number of shares issued during period

623,941

Proceeds from issue of ordinary shares | $

$ 779,924

Shares issued price per share | $ / shares

$ 1.25

$ 1.25

Special Warrants [Member]

Disclosure of classes of share capital [line items]

Number of warrants deemed to be exercised

16,000

Proceeds for warrants issued | $

$ 22,875

Number of warrants, Issued

18,300

18,300

Warrants issued, price per warrant | $ / shares

$ 1.25

Number of issued warrants rescinded

2,300

Refund from issued warrants rescinded | $

$ 2,875

Amount of escrow proceeds released | $

$ 20,000

Escrowed share purchase warrants [Member]

Disclosure of classes of share capital [line items]

Number of warrants exercised

1,948,000

Weighted average exercise price, Exercised | $ / shares

$ 0.05

Gross proceeds from warrants exercised | $

$ 97,400

Stock Options [Member]

Disclosure of classes of share capital [line items]

Percentage of outstanding shares authorized under stock option plan

10%

Number of options granted

80,000

895,807

150,000

Weighted average exercise price of options granted | $ / shares

$ 2.46

$ 4.29

$ 1.25

Number of options cancelled

20,000

190,000

20,000

Weighted average remaining contractual life of outstanding share options

3 years 4 months 20 days

4 years 3 months 10 days

Stock Options [Member] | Consultant [Member]

Disclosure of classes of share capital [line items]

Number of options granted

8,807

Weighted average exercise price of options granted | $ / shares

$ 7.64

Exercise price, stock options granted | $ / shares

7.64

Share price, stock options granted | $ / shares

$ 7.64

Option life, stock options granted | Year

3

Volatility rate, stock options granted

100%

Discount rate, stock options granted

0.55%

Number of options cancelled | Shares

90,000

Stock Options [Member] | Consultant [Member] | On the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Consultant [Member] | On the first anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Consultant [Member] | On the second anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Consultant [Member] | On the third anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director [Member]

Disclosure of classes of share capital [line items]

Number of options granted

80,000

Weighted average exercise price of options granted | $ / shares

$ 2.46

Exercise price, stock options granted | $ / shares

2.46

Share price, stock options granted | $ / shares

$ 2.4

Option life, stock options granted | Year

5

Volatility rate, stock options granted

147.31%

Discount rate, stock options granted

3.33%

Number of options cancelled | Shares

100,000

Stock Options [Member] | Director [Member] | On the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director [Member] | On the first anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director [Member] | On the second anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director [Member] | On the third anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Chief Financial Officer, two directors and seven consultants [Member]

Disclosure of classes of share capital [line items]

Number of options granted

467,000

Weighted average exercise price of options granted | $ / shares

$ 1.25

Exercise price, stock options granted | $ / shares

1.25

Share price, stock options granted | $ / shares

$ 1.25

Option life, stock options granted | Year

5

Volatility rate, stock options granted

100%

Discount rate, stock options granted

0.43%

Stock Options [Member] | Three Consultants [Member]

Disclosure of classes of share capital [line items]

Number of options granted

240,000

Weighted average exercise price of options granted | $ / shares

$ 7.6

Exercise price, stock options granted | $ / shares

7.6

Share price, stock options granted | $ / shares

$ 5.98

Option life, stock options granted | Year

5

Volatility rate, stock options granted

100%

Discount rate, stock options granted

0.92%

Stock Options [Member] | Director and Consultant [Member]

Disclosure of classes of share capital [line items]

Number of options granted

180,000

Weighted average exercise price of options granted | $ / shares

$ 7.6

Exercise price, stock options granted | $ / shares

7.6

Share price, stock options granted | $ / shares

$ 5.55

Option life, stock options granted | Year

5

Volatility rate, stock options granted

100%

Discount rate, stock options granted

0.84%

Stock Options [Member] | Director and Consultant [Member] | On the first anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director and Consultant [Member] | On the second anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director and Consultant [Member] | On the third anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Stock Options [Member] | Director and Consultant [Member] | On the fourth anniversary of the grant date [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Restricted Share Units [Member]

Disclosure of classes of share capital [line items]

Percentage of outstanding shares authorized under stock option plan

10%

Issuance of RSU | $

$ 35,000

$ 25,000

Estimated fair value of equity settled RSUs granted | $

$ 181,250

Remaining life (Years) of RSUs

3 years 4 months 17 days

3 years 10 months 28 days

Restricted Share Units [Member] | Director [Member]

Disclosure of classes of share capital [line items]

Issuance of RSU | $

$ 100,000

Estimated fair value of equity settled RSUs granted | $

$ 127,000

Restricted Share Units [Member] | Director [Member] | Subsequent events [Member]

Disclosure of classes of share capital [line items]

Number of units issued

1,100,000

Restricted Share Units [Member] | Director [Member] | On the date of grant [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

Restricted Share Units [Member] | Director [Member] | Each on April 27, 2024, 2025 and 2026 [Member]

Disclosure of classes of share capital [line items]

Vesting percentage

25%

SHARE CAPITAL - Disclosure of n

SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details) - Stock Options [Member]	1 Months Ended	12 Months Ended
	Jan. 21, 2021 Shares	Sep. 30, 2022 shares $ / shares	Sep. 30, 2021 shares $ / shares	Sep. 30, 2020 shares $ / shares
Disclosure of classes of share capital [line items]
Number of options, Beginning Balance | shares		1,025,807	150,000	0
Number of options, Granted | shares		80,000	895,807	150,000
Number of options, Cancelled	(20,000)	(190,000)	(20,000)
Number of options, Ending Balance | shares		915,807	1,025,807	150,000
Weighted average exercise price, Beginning Balance		$ 3.9	$ 1.25	$ 0
Weighted average exercise price, Granted		2.46	4.29	1.25
Weighted average exercise price, Cancelled		4.59	1.25
Weighted average exercise price, Ending Balance		$ 3.64	$ 3.9	$ 1.25

SHARE CAPITAL - Disclosure of_2

SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details) - Stock Options [Member]	12 Months Ended
	Sep. 30, 2022 shares $ / shares	Sep. 30, 2021 shares	Sep. 30, 2020 shares	Sep. 30, 2019 shares
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	915,807	1,025,807	150,000	0
Options Outstanding and Exercisable, Remaining life (Years)	3 years 4 months 20 days	4 years 3 months 10 days
September 21, 2024 [Member]
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	8,807
Options Outstanding and Exercisable, Exercisable	8,807
Options Outstanding and Exercisable, Exercise price | $ / shares	$ 7.64
Options Outstanding and Exercisable, Remaining life (Years)	1 year 11 months 23 days
July 23, 2025 [Member]
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	150,000
Options Outstanding and Exercisable, Exercisable	150,000
Options Outstanding and Exercisable, Exercise price | $ / shares	$ 1.25
Options Outstanding and Exercisable, Remaining life (Years)	2 years 9 months 21 days
November 17, 2025 [Member]
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	357,000
Options Outstanding and Exercisable, Exercisable	122,333
Options Outstanding and Exercisable, Exercise price | $ / shares	$ 1.25
Options Outstanding and Exercisable, Remaining life (Years)	3 years 1 month 17 days
April 28, 2026 [Member]
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	240,000
Options Outstanding and Exercisable, Exercisable	80,000
Options Outstanding and Exercisable, Exercise price | $ / shares	$ 7.6
Options Outstanding and Exercisable, Remaining life (Years)	3 years 6 months 29 days
June 15, 2026 [Member]
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	80,000
Options Outstanding and Exercisable, Exercisable	20,000
Options Outstanding and Exercisable, Exercise price | $ / shares	$ 7.6
Options Outstanding and Exercisable, Remaining life (Years)	3 years 8 months 15 days
September 6, 2027 [Member]
Disclosure of classes of share capital [line items]
Options Outstanding and Exercisable, Number of options	80,000
Options Outstanding and Exercisable, Exercisable	20,000
Options Outstanding and Exercisable, Exercise price | $ / shares	$ 2.46
Options Outstanding and Exercisable, Remaining life (Years)	4 years 11 months 8 days

SHARE CAPITAL - Disclosure of_3

SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details) - Restricted Share Units [Member]	12 Months Ended
	Sep. 30, 2022 shares $ / shares
Disclosure of classes of share capital [line items]
Beginning Balance	380,000
Granted	160,000
Ending Balance	540,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at beginning of period | $ / shares	$ 1.25
Weighted average exercise price grant | $ / shares	5.91
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period | $ / shares	$ 2.63
Equity settled [Member]
Disclosure of classes of share capital [line items]
Beginning Balance	380,000
Granted	160,000
Ending Balance	540,000
Cash settled [Member]
Disclosure of classes of share capital [line items]
Beginning Balance	0
Granted	0
Ending Balance	0

SHARE CAPITAL - Disclosure of_4

SHARE CAPITAL - Disclosure of number of outstanding and exercisable restricted share units (Details) - Restricted Share Units [Member]	12 Months Ended
	Sep. 30, 2022 shares $ / shares	Sep. 30, 2021 shares $ / shares
Disclosure of classes of share capital [line items]
Number of RSU's Outstanding	540,000	380,000
Exercise price | $ / shares	$ 2.63	$ 1.25
Remaining life (Years) of RSUs	3 years 4 months 17 days	3 years 10 months 28 days
July 23, 2025 [Member]
Disclosure of classes of share capital [line items]
Number of RSU's Outstanding	150,000
Number of RSUs Exercisable	75,000
Exercise price | $ / shares	$ 1.25
Remaining life (Years) of RSUs	2 years 9 months 21 days
September 18, 2025 [Member]
Disclosure of classes of share capital [line items]
Number of RSU's Outstanding	230,000
Number of RSUs Exercisable	115,000
Exercise price | $ / shares	$ 1.25
Remaining life (Years) of RSUs	2 years 11 months 19 days
February 1, 2027 [Member]
Disclosure of classes of share capital [line items]
Number of RSU's Outstanding	25,000
Number of RSUs Exercisable	0
Exercise price | $ / shares	$ 3.05
Remaining life (Years) of RSUs	4 years 4 months 2 days
February 1, 2027 [Member]
Disclosure of classes of share capital [line items]
Number of RSU's Outstanding	35,000
Number of RSUs Exercisable	0
Exercise price | $ / shares	$ 3
Remaining life (Years) of RSUs	4 years 4 months 2 days
April 27, 2027 [Member]
Disclosure of classes of share capital [line items]
Number of RSU's Outstanding	100,000
Number of RSUs Exercisable	25,000
Exercise price | $ / shares	$ 7.64
Remaining life (Years) of RSUs	4 years 6 months 29 days

SHARE CAPITAL - Disclosure of s

SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details) - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Disclosure of classes of share capital [line items]
Share-based compensation expense	$ 875,056	$ 880,615	$ 161,300
Equity settled [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	875,056	880,615	161,300
Equity settled [Member] | Stock Options [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	643,911	643,963	138,000
Equity settled [Member] | Restricted Share Units [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	231,145	236,652	23,300
Cash settled [Member] | Restricted Share Units [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	$ 0	$ 0	$ 0

SHARE CAPITAL - Disclosure of_5

SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details) - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Disclosure of classes of share capital [line items]
Share-based compensation expense	$ 875,056	$ 880,615	$ 161,300
Consulting fees [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	3,858	8,045	0
Directors' compensation [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	99,438	136,612	0
Marketing, advertising and investor relations [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	0	3,696	0
Professional fees [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	0	23,126	0
Research and development [Member]
Disclosure of classes of share capital [line items]
Share-based compensation expense	$ 771,760	$ 709,136	$ 161,300

SHARE CAPITAL - Disclosure of

SHARE CAPITAL - Disclosure of number and weighted average exercise prices of warrants (Details) - Warrants [Member] - $ / shares		1 Months Ended	12 Months Ended
	Nov. 02, 2020	Aug. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Disclosure of classes of share capital [line items]
Number of warrants, Beginning Balance			3,974,204	4,079,600
Number of warrants, Issued		134,040	3,083,198	1,709,938
Number of warrants, Issued - broker				132,666
Number of warrants, Issued - compensation warrants			225,198
Number of warrants, Exercised			(2,874,998)	(1,948,000)
Number of warrants, Ending Balance			4,407,602	3,974,204
Weighted average exercise price, Beginning Balance			$ 4.35	$ 0.05
Weighted average exercise price, Issued			1.76	9.46
Weighted average exercise price, Issued - broker				7.57
Weighted average exercise price, Issued - compensation warrants			1.4
Weighted average exercise price, Exercised			0.68	0.05
Weighted average exercise price, Ending Balance	$ 0.05		$ 4.78	$ 4.35

SHARE CAPITAL - Disclosure of_6

SHARE CAPITAL - Disclosure of number of outstanding warrants (Details) - Warrants [Member] - $ / shares	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Nov. 02, 2020	Nov. 01, 2020	Sep. 30, 2020
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	4,407,602	3,974,204			4,079,600
Warrants Outstanding, Exercise price	$ 4.78	$ 4.35	$ 0.05	$ 0.125	$ 0.05
July 30, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	314,800
Warrants Outstanding, Exercise price	$ 0.05
Warrants Outstanding, Remaining life (Years)	1 year 9 months 29 days
March 17, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	1,697,438
Warrants Outstanding, Exercise price	$ 9.46
Warrants Outstanding, Remaining life (Years)	1 year 5 months 15 days
March 17, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	132,666
Warrants Outstanding, Exercise price	$ 7.57
Warrants Outstanding, Remaining life (Years)	1 year 5 months 15 days
August 30, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	2,037,500
Warrants Outstanding, Exercise price	$ 1.76
Warrants Outstanding, Remaining life (Years)	1 year 11 months 1 day
August 30, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	134,040
Warrants Outstanding, Exercise price	$ 1.76
Warrants Outstanding, Remaining life (Years)	1 year 11 months 1 day
August 30, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding, Number of warrants	91,158
Warrants Outstanding, Exercise price	$ 1.76
Warrants Outstanding, Remaining life (Years)	1 year 11 months 1 day

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details) - CAD ($)	Sep. 30, 2022	Sep. 30, 2021
Disclosure of transactions between related parties [abstract]
Accounts payable and accrued liabilities	$ 105,181

RELATED PARTY TRANSACTIONS - Di

RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details) - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Disclosure of transactions between related parties [abstract]
Professional fees	$ 144,000	$ 87,074	$ 22,575
Research and development	572,700	772,596	26,777
Consulting fees	174,215	0	0
Share-based compensation included in directors' compensation	99,438	136,612	0
Share-based compensation included in professional fees	0	23,126	0
Share-based compensation included in research and development	123,052	236,652	161,300
Total expenses related to key management personnel	$ 1,113,405	$ 1,256,060	$ 210,652

CONTRACTUAL OBLIGATIONS (Narrat

CONTRACTUAL OBLIGATIONS (Narrative) (Details)

1 Months Ended

5 Months Ended

12 Months Ended

Apr. 11, 2022 USD ($) shares

Feb. 11, 2022 Shares

Nov. 06, 2020 USD ($)

Oct. 09, 2020 USD ($) Shares

Jun. 05, 2020 Shares shares

Nov. 01, 2021 CAD ($) shares

Aug. 31, 2021 USD ($)

Apr. 23, 2021 CAD ($) shares

Apr. 23, 2021 USD ($) shares

Mar. 31, 2021 USD ($)

Jan. 21, 2021 Shares

Nov. 17, 2020 Shares

Apr. 28, 2021 USD ($) Shares

Sep. 30, 2022 CAD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 CAD ($)

Sep. 30, 2020 CAD ($)

Disclosure Of Contractual Obligation [Line Items]

Research and development expense

$ 12,180,938

$ 6,313,988

$ 354,852

License agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Signing fee

$ 100,000

Option fees paid

$ 15,000

Signing fee, net of option fees paid

$ 105,502

Signing fee, shares issued | shares

63,000

63,000

Percentage of royalties on net sales under $1 billion

3%

3%

Percentage of royalties on net sales over $2 billion

4.50%

4.50%

Description of sublicensee revenue of royalty payment accrues

royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter;

royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter;

Annual minimum royalties - Years 1 and 2

Annual minimum royalties - Year 3

5,000

Annual minimum royalties - Year 4

15,000

Annual minimum royalties - Year 5

35,000

Annual minimum royalties - Year 6 and thereafter

50,000

Annual minimum royalties after first commercial sale

250,000

Licensing agreement - prior to any sublicensing agreements, joint ventures or change of control [Member]

Disclosure Of Contractual Obligation [Line Items]

Milestone payments upon dosing first patient in Phase I trial

10,000

Milestone payments upon dosing first patient in the first Phase II trial

50,000

Milestone payments upon dosing first patient in the first Phase III trial

250,000

Milestone payments upon first commercial sale of each clinical indication

2,000,000

Licensing agreement - after any sublicensing agreements, joint ventures or change of control [Member]

Disclosure Of Contractual Obligation [Line Items]

Milestone payments upon dosing first patient in the first Phase II trial

250,000

Milestone payments upon dosing first patient in the first Phase III trial

500,000

Milestone payments upon first commercial sale of each clinical indication

$ 2,000,000

Independent Consultant Agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of options granted | Shares

150,000

Number of RSUs granted | Shares

380,000

Monthly fee authorized by Board of Directors

$ 25,000

$ 15,000

Number of unvested restricted share units cancelled | shares

190,000

Independent Contractor Agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Monthly fee authorized by Board of Directors

$ 25,000

15,000

Letter agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of restricted stock issued for compensation | shares

11,200

Amount of non-refundable monthly retainer as service compensation

$ 5,000

Karl Deisseroth Agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Monthly fee authorized by Board of Directors

$ 4,167

Shares issued to a consultant | shares

25,000

Scientific advisory board agreements [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of options granted | Shares

130,000

Number of RSUs granted | Shares

60,000

Number of options cancelled | Shares

20,000

Scientific advisory board agreements [Member] | Bottom of range [member]

Disclosure Of Contractual Obligation [Line Items]

Advisor hourly rate

$ 150

Scientific advisory board agreements [Member] | Top of range [member]

Disclosure Of Contractual Obligation [Line Items]

Advisor hourly rate

$ 160

Consulting agreements [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of options granted | Shares

90,000

302,000

Monthly fee authorized by Board of Directors

$ 15,000

Advisor hourly rate

$ 130

Research and development expense

$ 66,764

Consulting agreements [Member] | Bottom of range [member]

Disclosure Of Contractual Obligation [Line Items]

Advisor hourly rate

$ 30

$ 400

Consulting agreements [Member] | Top of range [member]

Disclosure Of Contractual Obligation [Line Items]

Advisor hourly rate

$ 600

$ 600

January 1, 2022 | Letter agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of restricted stock issued for compensation | shares

3,800

April 1, 2022 | Letter agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of restricted stock issued for compensation | shares

3,700

July 1, 2022 | Letter agreement [Member]

Disclosure Of Contractual Obligation [Line Items]

Number of restricted stock issued for compensation | shares

3,700

FINANCIAL INSTRUMENTS AND CAP_3

FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)	Sep. 30, 2022 AUD ($)	Sep. 30, 2022 CAD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 CAD ($)	Sep. 30, 2020 CAD ($)	Sep. 30, 2019 CAD ($)
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents		$ 11,627,913		$ 19,760,015	$ 799,929	$ 79,991
Prepaids		164,429		168,207
Current liabilities		1,472,489		$ 638,573
Credit risk [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents		$ 11,627,913
Foreign exchange risk [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	$ 27,123		$ 862,731
Trade receivables	42,000		30,102
Prepaids	13,417		116,276
Current liabilities	$ 215,218		$ 785,439
Percentage of foreign currency fluctuation in US and Australia dollar against Canadian dollar	10%	10%	10%
Foreign currency fluctuation impact on net comprehensive loss		$ 19,000
Liquidity risk [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents		11,627,913
Current liabilities		$ 1,472,489

FINANCIAL INSTRUMENTS AND CAP_4

FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details) - CAD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
FVTPL
Cash and cash equivalents	$ 11,627,913	$ 19,760,015	$ 799,929	$ 79,991
Amortized cost
Accounts payable and accrued liabilities	1,404,561	638,573
FVTPL [Member]
FVTPL
Cash	11,541,663	19,673,765
Guaranteed investment certificate	86,250	86,250
Cash and cash equivalents	11,627,913	19,760,015
Amortized cost [Member]
Amortized cost
Accounts payable and accrued liabilities	$ 1,404,561	$ 638,573

RESEARCH AND DEVELOPMENT - Disc

RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details) - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Research And Development [Line Items]
Research and development expense	$ 12,180,938	$ 6,313,988	$ 354,852
Laboratory costs [Member]
Research And Development [Line Items]
Research and development expense	146,649	82,871	25,874
Novel drug development [Member]
Research And Development [Line Items]
Research and development expense	8,557,000	3,638,910	110,029
Patents and related payments [Member]
Research And Development [Line Items]
Research and development expense	73,645	513,302	13,895
Salary and subcontractors [Member]
Research And Development [Line Items]
Research and development expense	2,631,884	1,369,769	43,754
Share-based compensation [Member]
Research And Development [Line Items]
Research and development expense	$ 771,760	$ 709,136	$ 161,300

PREMISES LEASES (Narrative) (De

PREMISES LEASES (Narrative) (Details)	1 Months Ended	4 Months Ended	12 Months Ended				24 Months Ended
	Sep. 30, 2021 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 CAD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 CAD ($)	Sep. 30, 2020 CAD ($)	Sep. 01, 2024
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use asset			$ 138,863		$ 0
Interest expense on lease liabilities			2,173		$ 0	$ 0
Commercial laboratory [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Term of lease		1 year
Monthly base rent		$ 1,709
Lease cost			18,673
Apartment [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Term of lease	1 year
Monthly base rent	$ 5,300
Lease cost			$ 73,700
Extended term of lease							2 years
Monthly base rent for first year				$ 5,510
Monthly base rent for second year				$ 5,630

PREMISES LEASES - Disclosure of

PREMISES LEASES - Disclosure of right-of-use assets (Details)	12 Months Ended
	Sep. 30, 2022 CAD ($)
Presentation of leases for lessee [abstract]
As at September 30, 2021	$ 0
Inception of lease	144,900
Depreciation	(6,037)
As at September 30, 2022	$ 138,863

PREMISES LEASES - Disclosure _2

PREMISES LEASES - Disclosure of minimum lease payments in respect of lease liabilities (Details) - CAD ($)	Sep. 30, 2022	Sep. 30, 2021
Disclosure of maturity analysis of finance lease payments receivable [line items]
Undiscounted minimum lease payments:	$ 166,621
Effect of discounting	(26,710)
Present value of minimum lease payments	139,911	$ 0
Less current portion	(67,928)	0
Long-term portion	71,983	$ 0
Less than one year [Member]
Disclosure of maturity analysis of finance lease payments receivable [line items]
Undiscounted minimum lease payments:	86,112
Two to three years [Member]
Disclosure of maturity analysis of finance lease payments receivable [line items]
Undiscounted minimum lease payments:	$ 80,509

PREMISES LEASES - Disclosure _3

PREMISES LEASES - Disclosure of lease liability continuity (Details)	12 Months Ended
	Sep. 30, 2022 CAD ($)
Presentation of leases for lessee [abstract]
As at September 30, 2021	$ 0
Inception of lease	144,900
Cash flows:
Principal payments	(4,989)
As at September 30, 2022	$ 139,911

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - CAD ($)	Sep. 30, 2022	Sep. 30, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital loss carry-forwards	$ 23,360,000
Tax authority of Canada [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital loss carry-forwards	21,545,000	$ 9,940,000
Tax authority of United States [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital loss carry-forwards	188,000	30,000
Tax authority of Australia [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital loss carry-forwards	$ 1,627,000	$ 7,000

INCOME TAXES - Disclosure of r

INCOME TAXES - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details) - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Major components of tax expense (income) [abstract]
Net loss	$ (14,964,941)	$ (8,650,763)	$ (480,377)
Statutory tax rate	27.26%	27.75%	27%
Expected income tax recovery	$ (4,079,645)	$ (2,400,311)	$ (129,702)
Deductible and non-deductible items	21,093	(256,939)	42,136
Change in deferred tax assets not recognized	4,058,552	2,657,250	87,566
Total income recovery	$ 0	$ 0	$ 0

INCOME TAXES - Disclosure of de

INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details) - CAD ($)	Sep. 30, 2022	Sep. 30, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences not recognized	$ 0	$ 0
Non-capital losses [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences not recognized	23,360,000	9,976,000
Share issue costs [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences not recognized	1,726,000	1,448,000
Intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences not recognized	0	(1,000)
Valuation allowance [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences not recognized	$ (25,086,000)	$ (11,423,000)

INCOME TAXES - Disclosure of n

INCOME TAXES - Disclosure of non-capital loss carry-forwards expiry (Details) - CAD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-Capital Losses	$ 23,360,000
Tax authority of Canada [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-Capital Losses	$ 21,545,000	$ 9,940,000
2019 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Year of Expiry	2039
Non-Capital Losses	$ 42,000
2020 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Year of Expiry	2040
Non-Capital Losses	$ 298,000
2021 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Year of Expiry	2041
Non-Capital Losses	$ 8,133,000
2022 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Year of Expiry	2042
Non-Capital Losses	$ 14,887,000

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details)					1 Months Ended		12 Months Ended
	Dec. 02, 2022 CAD ($) $ / shares $ / Shares shares	Dec. 01, 2022 Shares shares	Nov. 13, 2022 $ / shares	Nov. 13, 2022 USD ($) Shares	Aug. 30, 2022 $ / Shares shares	Mar. 17, 2021 $ / Shares shares	Sep. 30, 2022 CAD ($) shares
Disclosure of non-adjusting events after reporting period [line items]
Number of units issued					2,858,000	3,419,883
Units issued, price per unit | $ / Shares					1.4	7.57
Subsequent events [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of warrants exercised							144,000
Gross proceeds from warrants exercised | $							$ 253,440
Subsequent events [Member] | Independent contractor agreement to serve as Chief Medical Officer [Member]
Disclosure of non-adjusting events after reporting period [line items]
Signing bonus of independent contractor agreement | $				$ 35,000
Annual fee authorized by board of directors | $				$ 205,000
Number of options granted | Shares				300,000
Exercise price, stock options granted | $ / shares			$ 1.65
Subsequent events [Member] | Independent contractor agreement to serve as Chief Medical Officer [Member] | On the first anniversary of the grant date [Member]
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage				25%
Subsequent events [Member] | Independent contractor agreement to serve as Chief Medical Officer [Member] | On the second anniversary of the grant date [Member]
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage				25%
Subsequent events [Member] | Independent contractor agreement to serve as Chief Medical Officer [Member] | On the third anniversary of the grant date [Member]
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage				25%
Subsequent events [Member] | Independent contractor agreement to serve as Chief Medical Officer [Member] | On the fourth anniversary of the grant date [Member]
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage				25%
Subsequent events [Member] | Consultant [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of options cancelled | Shares		80,000
Subsequent events [Member] | Restricted share units [Member] | Director [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of units issued		1,100,000
Subsequent events [Member] | Non-brokered private placement [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of warrants, Issued	666,000
Gross proceeds from non-brokered private placement | $	$ 2,049,334
Warrants issued, price per warrant | $ / shares	$ 1.249
Number of units issued	974,000
Units issued, price per unit | $ / Shares	1.25
Description of warrants	Each PFW is exercisable into one Unit at an exercise price of $0.001 per Unit on the date that is the earlier of (a) the date the holder thereof elects to exercise the PFWs and pays the exercise price, and (b) December 2, 2024. Each Unit is comprised of one common share and one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company at an exercise price of $1.35 per share until December 2, 2024.